Zhitong Finance App News and Platinum Pharmaceutical-B (02142) announced that the company's partner company Solstice Oncology (Solstice) has completed Series A financing of 225 million US dollars and officially started operations. The funding round was led by RA Capital Management, with participation from Canaan Partners, Forbion and other investors.

Solstice is a clinical-stage oncology immunology company dedicated to intervening in cancer earlier in the new adjuvant treatment phase. Solstice is promoting its main drug candidate, prusubimab, a second-generation Fc enhanced antibody with differentiated properties targeting cytotoxic T lymphocyte-associated protein 4 (CTLA-4). It is currently being promoted in two clinical indications. One of them is microsatellite-stable (MSS) colon cancer, and the other indication has not been disclosed. A phase 2 clinical study is evaluating the efficacy of prusubimab combined with pabolizumab on MSS clinical stage II-III colon cancer in the new adjuvant treatment. MSS is the most common subtype of colon cancer, and so far this patient group has not benefited from immunotherapy. The phase 2 clinical trial is expected to start enrolling patients in the early fourth quarter of 2026, and the study data is expected to be available in the second half of 2027.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.